Casirivimab and imdevimab: Guidance for Chief Pharmacists

Published Last updated See all updates

The SPS guidance on handling casirivimab and imdevimab has now been withdrawn and all stocks have expired

January 2022 Update

Casirivimab and imdevimab (Ronapreve) was introduced as a treatment for COVID-19 in September 2021.

At the point of publishing this article, casirivimab and imdevimab is no longer recommended within current NHS guidance for use of neutralising monoclonal antibodies to treat patients with COVID-19.

All existing UK stocks of casirivimab and imdevimab “pandemic pack” 300mg in 2.5mL and 1332mg in 11.1mL vials have now expired, and no further extension to expiry of the stock is anticipated. Dispose of all expired Casirivimab and imdevimab “pandemic pack” vials in accordance with local waste procedures.

Existing SPS advice on the handling and expiry extension of Casirivimab and imdevimab “pandemic pack” vials has now been withdrawn.

Update history

  1. Guidance withdrawn as all existing UK stocks of casirivimab and imdevimab “pandemic packs" now expired
  1. PDF version on institutional readiness document removed as all information now contained within web pages
  1. Removed reference to protecting the prepared infusion from light, as this is not required.
  1. Institutional readiness doc updated to include reference to use of separate kit for consumables due to incompatibility of some consumables with refrigerated storage. Additional information included on batch number format.
  1. Published